• 1
    Willett WC, Manson JE, Stampfer MJ et al. Weight, weight change, and coronary heart disease in women. Risk within the ‘normal’ weight range. JAMA 1995; 273: 461465.
  • 2
    Rabkin SW, Mathewson FA, Hsu PH. Relation of body weight to development of ischemic heart disease in a cohort of young North Am men after a 26 year observation period: the Manitoba Study. Am J Cardiol 1977; 39: 452458.
  • 3
    Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67: 968977.
  • 4
    Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002; 162: 18671872.
  • 5
    Manson JE, Colditz GA, Stampfer MJ et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 1990; 322: 882889.
  • 6
    Dagenais GR, Yi Q, Mann JF et al. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J 2005; 149: 5460.
  • 7
    Poirier P, Giles TD, Bray GA et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006; 113: 898918.
  • 8
    Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683689.
  • 9
    Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 27092716.
  • 10
    López-Candales A. Metabolic syndrome X: a comprehensive review of the pathophysiology and recommended therapy. J Med 2001; 32: 283300.
  • 11
    Genest JJ, McNamara JR, Salem DN, Schaefer EJ. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol 1991; 67: 11851189.
  • 12
    Haffner SM. American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care 2004; 27 (Suppl 1):S68S71.
  • 13
    Hopkins PN, Heiss G, Ellison RC et al. Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study. Circulation 2003; 108: 519523.
  • 14
    Semenkovich CF. Insulin resistance and atherosclerosis. J Clin Invest 2006; 116: 18131822.
  • 15
    Szapary PO, Rader DJ. The triglyceride-high-density lipoprotein axis: an important target of therapy? Am Heart J 2004; 148: 211221.
  • 16
    Mooradian AD, Haas MJ, Wong NCW. The effect of select nutrients on serum high density lipoprotein cholesterol and apolipoprotein A-I levels. Endocr Rev 2006; 27: 216.
  • 17
    Mooradian AD, Haas MJ, Wong NCW. Transcriptional control of apolipoprotein A-I gene expression in diabetes mellitus. Diabetes 2004; 53: 513520.
  • 18
    Hachem S, Mooradian AD. Familial dyslipidemias: an overview of pathophysiology and management. Drugs 2006; 66: 19491969.
  • 19
    Nissen SE, Tardif J-C, Nicholls SJ et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007; 356: 13041316.
  • 20
    Borggreve SE, Hillege HL, Wolffenbuttel BH et al. An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study. J Clin Endocrinol Metab 2006; 91: 33823388.
  • 21
    Vaisar T, Pennathur S, Green PS et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007; 117: 746756.
  • 22
    Kawahiri M, Maugeais C, Rader D. High-density lipoprotein metabolism: molecular targets for new therapies for atherosclerosis. Curr Atheroscler Rep 2000; 2: 363372.
  • 23
    Wang M, Briggs MR. HDL: the metabolism, function, and therapeutic importance. Chem Rev 2004; 104: 119137.
  • 24
    Zheng L, Nukuna B, Brennan ML et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004; 114: 529541.
  • 25
    Navab M, Anantharamaiah GM, Reddy ST et al. Mechanisms of disease: proatherogenic HDL—an evolving field. Nat Clin Pract Endocrinol Metab 2006; 2: 504511.
  • 26
    Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356359.
  • 27
    Park YW, Zhu S, Palaniappan L et al. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med 2003; 163: 427436.
  • 28
    Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52: 12101214.
  • 29
    Meigs JB, Wilson PW, Nathan DM et al. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes 2003; 52: 21602167.
  • 30
    Smith SC. Multiple risk factors for cardiovascular disease and diabetes mellitus. Am J Med 2007; 120 (3 Suppl 1):S3S11.
  • 31
    Brown CD, Higgins M, Donato KA et al. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res 2000; 8: 605619.
  • 32
    Mooradian AD, Albert SG, Hass MJ. Low serum HDL cholesterol in obese subjects with normal serum triglycerides: the role of insulin resistance and inflammatory cytokines. Diabetes Obes Metab 2007; 9: 441443.
  • 33
    Borggreve SE, De Vries R, Dullaart RP. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin: cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003; 33: 10511069.
  • 34
    Vajo Z, Terry JG, Brinton EA. Increased intra-abdominal fat may lower HDL levels by increasing the fractional catabolic rate of Lp A-I in postmenopausal women. Atherosclerosis 2002; 160: 495501.
  • 35
    de Vries R, Kerstens MN, Sluiter WJ et al. Cellular cholesterol efflux to plasma from moderately hypercholesterolaemic type 1 diabetic patients is enhanced, and is unaffected by simvastatin treatment. Diabetologia 2005; 48: 11051113.
  • 36
    de Vries R, Groen AK, Perton FG et al. Increased cholesterol efflux from cultured fibroblasts to plasma from transfer hypertriglyceridemic type 2 diabetic patients: roles of pre beta-HDL, phospholipid protein and cholesterol esterification. Atherosclerosis 2008; 196: 733741.
  • 37
    Dullaart RP, De Vries R, Scheek L et al. Type 2 diabetes mellitus is associated with differential effects on plasma cholesteryl ester transfer protein and phospholipid transfer protein activities and concentrations. Scand J Clin Lab Invest 2004; 64: 205215.
  • 38
    Murao K, Wada Y, Nakamura T et al. Effects of glucose and insulin on rat apolipoprotein A-I gene expression. J Biol Chem 1998; 273: 1895918965.
  • 39
    Lam JK, Matsubara S, Mihara K et al. Insulin induction of apolipoprotein A, role of Sp1. Biochemistry 2003; 42: 26802690.
  • 40
    Haas MJ, Horani M, Mreyoud A et al. Suppression of apolipoprotein AI gene expression in HepG2 cells by TNF alpha and IL-1beta. Biochem Biophys Acta 2003; 1623: 120128.
  • 41
    Beers A, Haas MJ, Wong NCW, Mooradian AD. Inhibition of apolipoprotein AI gene expression by tumor necrosis factor alpha: roles for MEK/ERK and JNK signaling. Biochemistry 2006; 45: 24082413.
  • 42
    Le NA, Ginsburg HN. Heterogeneity of apolipoprotein A-I turnover in subjects with reduced concentrations of plasma high density lipoprotein cholesterol. Metabolism 1988; 37: 614617.
  • 43
    Mooradian AD, Haas MJ, Wong NCW, Chehade JH. Apolipoprotein A-I expression in rats is not altered by troglitazone. Exp Biol Med (Maywood) 2002; 227: 10011005.
  • 44
    Sakamoto J, Kimura H, Moriyama S et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 2000; 278: 704711.
  • 45
    Duvillard L, Pont F, Florentin E, Gambert P, Vergès B. Inefficiency of insulin therapy to correct apolipoprotein A-I metabolic abnormalities in non-insulin-dependent diabetes mellitus. Atherosclerosis 2000; 152: 229237.
  • 46
    Mooradian AD, Wong NCW, Shah GN. Apolipoprotein A1 expression in young and aged rats is modulated by dietary carbohydrates. Metabolism 1997; 46: 11321136.
  • 47
    Shah NG, Wong NCW, Mooradian AD. Age-related changes in apolipoprotein A-I expression. Biochem Biophys Acta 1995; 1259: 277282.
  • 48
    Population Studies Data Book Volume 1. The Lipid Research Clinics. NIH publication No. 80-1527, July 1980.
  • 49
    Mooradian AD. Obesity: a rational target for managing diabetes mellitus. Growth Horm IGF Res 2001; 11 (Suppl A):S79S83.
  • 50
    Haas MJ, Horani MH, Wong NCW, Mooradian AD. Induction of the apolipoprotein AI promoter by Sp1 is repressed by saturated fatty acids. Metabolism 2004; 53: 13421348.
  • 51
    Mooradian AD, Chehade J, Hurd R, Haas MJ. Monosaccharide-enriched diets cause hyperleptinemia without hypophagia. Nutrition 2000; 16: 439441.
  • 52
    Mooradian AD, Chehade J. Serum leptin response to endogenous hyperinsulinemia in aging rats. Mech Ageing Dev 2000; 115: 101106.
  • 53
    Dussault I, Forman BM. Prostaglandins and fatty acids regulate transcriptional signaling via the peroxisome proliferator activated receptor nuclear receptors. Prostaglandins other Lipid Mediat 2000; 62: 113.
  • 54
    Vu-Dac N, Chopin-Delannoy S, Gervois P et al. The nuclear receptors peroxisome proliferator-activated receptor α and Rev-erb α mediate the species-specific regulation of apolipoprotein A1 expression by fibrates. J Biol Chem 1998; 273: 2571325720.
  • 55
    Horani M, Gobal F, Haas MJ, Wong NCW, Mooradian AD. Cyclooxygenase (COX) inhibition is associated with downregulation of apolipoprotein AI promoter activity in cultured hepatoma cell line-HepG2. Metabolism 2004; 53: 174181.
  • 56
    Weisweiler P. Plasma lipoproteins and lipase and lecithin: cholesterol acyltransferase activities in obese subjects before and after weight reduction. J Clin Endocrinol Metab 1987; 65: 969973.
  • 57
    Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 1992; 56: 320328.
  • 58
    James WP, Astrup A, Finer N et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000; 356: 21192125.
  • 59
    Després JP, Golay A, Sjöström L. Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 21212134.
  • 60
    Ligaray K, Hachem S, Mazza A et al. Repression of apolipoprotein A-I gene expression by anandamide. Diabetes 2007; 56 (Suppl 1):A56.
  • 61
    Davidson MH, Hauptman J, DiGirolamo M et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235242.
  • 62
    Sjöström L, Rissanen A, Andersen T et al. Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998; 352: 167172.
  • 63
    Sjöström L, Lindroos AK, Peltonen M et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 35: 26832693.
  • 64
    American Heart Association Nutrition Committee, Lichtenstein AH, Appel LJ et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation 2006; 114: 8296.
  • 65
    Bantle JP, Wylie-Rosett J, Albright AL et al. Nutrition recommendations and interventions for diabetes—2006: a position statement of the American Diabetes Association. Diabetes Care 2006; 29: 21402157.
  • 66
    Krauss RM. Dietary and genetic probes of atherogenic dyslipidemia. Arterioscler Thromb Vasc Biol 2005; 25: 22652272.
  • 67
    Berglund L, Oliver EH, Fontanez N et al. HDL-subpopulation patterns in response to reductions in dietary total and saturated fat intakes in healthy subjects. Am J Clin Nutr 1999; 70: 9921000.
  • 68
    Pelkman CL, Fishell VK, Maddox DH et al. Effects of moderate-fat (from monounsaturated fat) and low-fat weight-loss diets on the serum lipid profile in overweight and obese men and women. Am J Clin Nutr 2004; 79: 204212.
  • 69
    Slyper A, Jurva J, Pleuss J, Hoffmann R, Gutterman D. Influence of glycemic load on HDL cholesterol in youth. Am J Clin Nutr 2005; 81: 376379.
  • 70
    Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr 2003; 77: 11461155.
  • 71
    Meksawan K, Pendergast DR, Leddy JJ et al. Effect of low and high fat diets on nutrient intakes and selected cardiovascular risk factors in sedentary men and women. J Am Coll Nutr 2004; 23: 131140.
  • 72
    Hatahet W, Cole L, Kudchodkar BJ, Fungwe TV. Dietary fats differentially modulate the expression of lecithin: cholesterol acyltransferase, apoprotein-A1 and scavenger receptor b1 in rats. J Nutr 2003; 133: 689694.
  • 73
    Sánchez-Muniz FJ, Merinero MC, Rodríguez-Gil S et al. Dietary fat saturation affects apolipoprotein AII levels and HDL composition in postmenopausal women. J Nutr 2002; 132: 5054.
  • 74
    Walden CE, Retzlaff BM, Buck BL et al. Differential effect of National Cholesterol Education Program (NCEP) Step II diet on HDL cholesterol, its subfractions, and apoprotein A-I levels in hypercholesterolemic women and men after 1 year: the beFIT Study. Arterioscler Thromb Vasc Biol 2000; 20: 15801587.
  • 75
    Li Z, Otvos JD, Lamon-Fava S et al. Men and women differ in lipoprotein response to dietary saturated fat and cholesterol restriction. J Nutr 2003; 133: 34283433.
  • 76
    Harris WS. n-3 Fatty acids and lipoproteins: comparison of results from human and animal studies. Lipids 1996; 31: 243252.
  • 77
    Bays H. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. Am J Cardiol 2006; 98: 71i76i.
  • 78
    Brousseau ME, Ordovas JM, Osada J et al. Dietary monounsaturated and polyunsaturated fatty acids are comparable in their effects on hepatic apolipoprotein mRNA abundance and liver lipid concentrations when substituted for saturated fatty acids in cynomolgus monkeys. J Nutr 1995; 125: 425436.
  • 79
    Judd JT, Baer DJ, Clevidence BA et al. Dietary cis and trans monounsaturated and saturated FA and plasma lipids and lipoproteins in men. Lipids 2002; 37: 123131.
  • 80
    Methane NR, Welty FK, Barrett PH et al. Dietary hydrogenated fat increases high-density lipoprotein apoA-I catabolism and decreases low-density lipoprotein apoB-100 catabolism in hypercholesterolemic women. Arterioscler Thromb Vasc Biol 2004; 24: 10921097.
  • 81
    Zock PL, Katan MB. Hydrogenation alternatives: effects of trans fatty acids and stearic acid versus linoleic acid on serum lipids and lipoproteins in humans. J Lipid Res 1992; 33: 399410.
  • 82
    Mensink RP, Katan MB. Effect of dietary trans fatty acids on high-density and low-density lipoprotein cholesterol levels in healthy subjects. N Engl J Med 1990; 323: 439445.
  • 83
    Reiser S, Powell AS, Scholfield DJ et al. Blood lipids, lipoproteins, apoproteins, and uric acid in men fed diets containing fructose or high-amylose cornstarch. Am J Clin Nutr 1989; 49: 832839.
  • 84
    Osei K, Bossetti B. Dietary fructose as a natural sweetener in poorly controlled type 2 diabetes: a 12-month crossover study of effects on glucose, lipoprotein and apolipoprotein metabolism. Diabet Med 1989; 6: 506511.
  • 85
    Lichtenstein AH. Thematic review series: patient-oriented research. Dietary fat, carbohydrate, and protein: effects on plasma lipoprotein patterns. J Lipid Res 2006; 47: 16611667.
  • 86
    Vega-López S, Lichtenstein AH. Dietary protein type and cardiovascular disease risk factors. Prev Cardiol 2005; 8: 3140.
  • 87
    Potter SM. Overview of proposed mechanism for the hypocholesterolemic effect of soy. J Nutr 1995; 125 (Suppl 3):S606S611.
  • 88
    Lamon-Fava S, Micherone D. Regulation of apoA-I gene expression: mechanism of action of estrogen and genistein. J Lipid Res 2004; 45: 106112.
  • 89
    Appel LJ, Sacks FM, Carey VJ et al. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. JAMA 2005; 294: 24552464.
  • 90
    Cheung MC, Zhao X-Q, Chait A, Albers JJ, Brown G. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler Thromb Vasc Biol 2001; 21: 13201326.
  • 91
    Mooradian AD, Haas MJ, Wadud K. Ascorbic acid and alpha-tocopherol down-regulate apolipoprotein A-I gene expression in HepG2 and Caco-2 cell lines. Metabolism 2006; 55: 159167.
  • 92
    Wehmeier K, Beers A, Haas MJ et al. Inhibition of apolipoprotein AI gene expression by 1,25-dihydroxyvitamin D3. Biochim Biophys Acta 2005; 1737: 1626.
  • 93
    Berthou L, Langouet S, Grude P et al. Negative regulation of Apo A-I gene expression by retinoic acid in rat hepatocytes maintained in a coculture system. Biochim Biophys Acta 1998; 1391: 329336.
  • 94
    Parikh SJ, Edelman M, Uwaifo GI et al. The relationship between obesity and serum 1,25-dihydroxy vitamin D concentrations in healthy adults. J Clin Endocrinol Metab 2004; 89: 11961199.
  • 95
    Snijder MB, van Dam RM, Visser M et al. Adiposity in relation to vitamin D status and parathyroid hormone levels: a population-based study in older men and women. J Clin Endocrinol Metab 2005; 90: 41194123.
  • 96
    Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care 2005; 28: 12281230.
  • 97
    Hahn S, Haselhorst U, Tan S et al. Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2006; 114: 577583.
  • 98
    Baer DJ, Judd JT, Clevidence BA et al. Moderate alcohol consumption lowers risk factors for cardiovascular disease in postmenopausal women fed a controlled diet. Am J Clin Nutr 2002; 75: 593599.
  • 99
    Rimm EB, Williams P, Fosher K, Criqui M, Stampfer MJ. Moderate alcohol intake and lowr risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ 1999; 319: 15231528.
  • 100
    Tam SP. Effect of ethanol on lipoprotein secretion in two human hepatoma cell lines, HepG2 and Hep3B. Alcohol Clin Exp Res 1992; 16: 10211028.
  • 101
    Williams PT. The relationships of vigorous exercise, alcohol, and adiposity to low and high high-density lipoprotein-cholesterol levels. Metabolism 2004; 53: 700709.
  • 102
    Wilund KR, Ferrell RE, Phares DA, Goldberg AP, Hagberg JM. Changes in high-density lipoprotein-cholesterol subfractions with exercise training may be dependent on cholesteryl ester transfer protein (CETP) genotype. Metabolism 2002; 51: 774778.
  • 103
    Halverstadt A, Phares DA, Ferrell RE et al. High-density lipoprotein-cholesterol, its subfractions, and responses to exercise training are dependent on endothelial lipase genotype. Metabolism 2003; 52: 15051511.